Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
Key Details
- 1Lucida Medical, a UK-based AI firm, raised $11.4 million in new funding.
- 2Their Prostate Intelligence (Pi) software uses MRI to help diagnose prostate cancer.
- 3The software is already deployed in up to 15 UK NHS hospitals.
- 4NHS invested around $3 million to use the platform, aiming for diagnoses within 28 days.
- 5The new funds will help pursue US FDA regulatory approval and expand to detect other clinical conditions.
Why It Matters
This funding supports efforts to scale AI-powered prostate cancer diagnosis, addressing critical radiology workforce shortages and speeding up patient pathways. US FDA approval could open access to broader markets and bring innovative diagnostic AI tools to more clinicians and patients.
Source
Radiology Business
Related News
•Radiology Business
Webinar to Showcase Successful AI Automation in Radiology Workflows
A webinar will provide insights from imaging leaders on expanding and optimizing AI-driven automation in radiology clinical workflows.
•AuntMinnie
AI Quantitative MRI and Amyloid PET Used for ARIA Monitoring in Alzheimer's
AI-driven MRI analysis complements Amyloid PET in detecting ARIA during Alzheimer's treatment.
•AuntMinnie
Radiomics Features Vary Between Manual and AI-Driven Segmentations
DL-based segmentations on CT and MRI show limited agreement and bias compared to manual segmentations, affecting radiomics model reliability.